Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-22-026974
Filing Date
2022-09-28
Accepted
2022-09-28 11:26:26
Documents
56
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 1089809
2 form10-k_001.jpg GRAPHIC 5096
3 ex31-1.htm EX-31.1 11390
4 ex31-2.htm EX-31.2 10619
5 ex32-1.htm EX-32.1 4307
6 ex32-2.htm EX-32.2 4242
  Complete submission text file 0001493152-22-026974.txt   4642718

Data Files

Seq Description Document Type Size
7 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nxen-20220630.xsd EX-101.SCH 35893
8 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nxen-20220630_cal.xml EX-101.CAL 36798
9 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nxen-20220630_def.xml EX-101.DEF 162987
10 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nxen-20220630_lab.xml EX-101.LAB 317913
11 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nxen-20220630_pre.xml EX-101.PRE 248699
50 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 524538
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

EIN.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-K | Act: 34 | File No.: 000-55320 | Film No.: 221273525
SIC: 2834 Pharmaceutical Preparations